38
25
53
15
61
90
84
51
40
64
28
101
130
138
International Diabetes Federation. IDF Homepage. International Diabetes Federation 2011. Available from: http://www.idf.org/.
Every 10 seconds... 2 people develop
DM The number of patients with diabetes worldwide is expected to
increase from 366 million in 2011 to 552 million in 2030
2
Number of patients, millions
North
America
and
Caribbean
South and
Central
America
Europe Africa India China Other
s
2011 2030
 Disease duration
 Degree of glycemic control.
Poor glycemic control
Delayed gastric emptying
EFFECTS
 Peristalsis
 Reflexive relaxation
 Sphincter tone
 Vascular flow
 Intestinal segmentation
MOST COMMON PROBLEMS
 Constipation
 Diarrhea
 Abdominal pain
 Nausea
 Vomiting
ESOPHAGUS
• Abnormal Motility (50-75%)
• Reduced number, amplitude & velocity of
peristalsis
• Increased spontaneous, spastic and repetitive
contractions
• Appearance of multipeaked contractions
•Impaired(prolonged) esophageal transit-
scintigraphy
• Reduced lower esophageal sphincter pressure
 Hyperglycemia impairs neutrophil function and
opsonization.
 Odynophagia
 ® Nystatin 1lakh U-3-5times/dy, Clotrimazole
10mg(troche) 5 times/dy or 500mg VT HS.
 Fluconazole- 200mg loading + 100mg/dy x
21dys
STOMACH
Type 1: Gastritis/Gastric Atrophy (5% to 10%).
Parietal cell antibodies (15% to 25%).
Pernicious Anemia (2.6% to 4%).
Reduced acid hence decreased ulcer incidence.
Increased risk of ulcer bleeding- microcirculatory
changes that impair mucosal integrity.
GASTROPARESIS DIABETICORUM
 Seen in upto 60%
 Insidious nature, Rarely acute- similar to vagotomy
 Nausea, vomiting, pain, bloating, early satiety,
flatulence, anorexia and postprandial regurgitation- 20%
 Changes in drug absorption
 Food retention- increase of bacteria toxins &
fermentation products- hypermotility and diarrhoea
Examination - succussion splash
● Scintigraphy- Solid and liquid emptying assessed.
Gastroparesis->60% @ 2hrs & >10% @ 4hrs.
● Saline loading- 800-1000ml.
● EGG- Increased frequency of antral dysrhythmias.
Phase 3 MMC are absent →bezoars.
Abnormal
Gastroduodenal pressure gradient
Fundal relaxation
Pylorospasm
TREATMENT
Glycemic control- Depo-insulin to prevent hypoglycaemic episodes
 DIET MODIFICATION:
Smaller/liquid meals, low-fat, low-fiber diet
Jejunal tube feeding/ TPN
 MEDICATIONS-
Prokinetics: Metoclopramide10to20mg, Erythromycin 125mgBD or TDS
or IV200mg over5to10minutesTDS, Domperidone 10 to 30 mg.
Antiemetics- (promethazine or prochlorperazine), scopolamine patch.
Low-dose TCA
5-HT3 receptor antagonists- odansetron, dronabinol
Ghrelin- improves gastric emptying
GES
A) Gastric pacing - improves gastric
emptying
B) Neurostimulation - controls
nausea/vomiting
Endoscopic therapy with injection of
botulinum toxin into the pyloric sphincter
Gastric resection (Partial or complete) in
medically refractory cases
GASTRIC ELECTRICAL STIMULATION-10 YEAR DATA
- Greater Symptom Reduction
- Improved Gastric Emptying  normalized in 23%
- Decreased Hb A1C levels  translates to fewer
complications
- Significant Weight Gain
- Reduction in Hospitalization Days
- Reduced Medication Usage (for gastroparesis)
McCallum, et al, Clin. Gastro & Hep. 9(4):314-319
TABETIC PAIN
 sharp, sudden pain
 With nausea, vomiting, anorexia and weight loss-
mimics intra-abdominal malignancy
 Diabetic radiculopathy of thoracic nerve roots
 The diagnosis- abnormal EMG of the anterior
abdominal wall muscles
DIABETIC ACIDOSIS
 Anorexia, nausea and vomiting- 75%
 Gastric dilatation- reduced gastric
motility→vomiting-(ketones and systemic acidosis)
 Abdominal pain-Acute apendicitis, Acute
pancreatitis-should be excluded
DIARRHEA
 Drugs- Metformin, ά-Glucosidase inhibitors
,sugarfree sweeteners.
 SIBO
 Pancreatic insufficiency
 Fast transit (and hyperthyroidism)
 Celiac disease(4%)
 Hormones- glucagon or somatostatin
 Autonomic neuropathy
CHRONIC DIARRHEA WITHOUT
STEATORRHEA
 Occur 5-10 years later, men > women: 22%
 Exact pathogenesis- still undetermined
 In young-long standing and uncontrolled diabetes.
 Diabetic night diarrhoea
 Hyperglycaemia, hypoglycemia and ketoacidosis.
 Barium transit- segmentation with mucous villous
atrophy, irregularity.
DIABETIC DIARRHEA WITH
STEATORRHEA
 Steatorrhea occurs when diarrhoea worsens: 75%
 Shows intermittent flow.
 More frequently, postpardial and they appear at
night
 Rarely fatty, watery and abundant
TREATMENT
 Strict control of blood glucose
 Broad spectrum antibiotics
 Vitamins, folic acid, liver extracts, bismuth, opiates, atropine
 Corticosteroids
 Clonidine (0.1 to 0.6 mg twice daily) stimulate intestinal
absorption
 Octreotide (50 to 100 subcutaneously, BD) in refractory
diabetic diarrhea
 Codeine sulfate (30 mg every six to eight hours),
 Diphenoxylate with atropine (Lomotil),
 Loperamide
 Psyllium hydrophilic mucilloid
DIABETES AND CELIAC
DISEASE
 Coexist (4%)-shared HLA class II genes and non-HLA
loci
 Found within 4 years of DM.
 Short stature, pubertal delay, - signs of vitamin deficit,
anemia, losing weight and pigmentation,osteoporosis,
and/or reproductive disorders
 Have poor glycemic control- hypoglycemic episodes,
and microvascular complications.
 Small intestine which shows villous atrophy and
abnormal superficial epithelium
 Malabsorbtion in diabetes-limited only to fats
 Respond to gluten free diet
LARGE INTESTINE
 Constipation
 Impaired gastrocolic reflex and delayed colonic
transit
 Ischemic colitis - luminal narrowing of
submucosal arterioles.
 Neuropathy damages the motility.
 Equally frequent and severe without
neuropathy
 Obstipation- nausea, vomiting, belching and
bloating.
MEGASIGMOID
SYNDROME
 Colon dilatation- neuropathy and the
paralysis of ganglia.
 Imitates acute intestinal pseudo-
obstruction.
 Obstipation- long standing and refractory.
 X-ray- dilatation of sigmoid colon.
 Mucosa of the large intestine- Normal.
 Bad prognosis.
 Treatment- Laxative (abuse).
FECAL INCONTINENCE
 The total stool volume is normal.
 Steatorrhea in 30%.
 Impaired internal anal sphincter resting tone and
reflexive internal sphincter relaxation.
 Reduced sensitivity of the rectum to distension.
 Management:
Antidiarrheal therapy
Biofeedback training
Sacral nerve stimulation
Surgery
In some patients incontinence remits spontaneously.
DIABETES – LIVER/BILIARY
HIGHER INCIDENCE OF ACUTE HEPATITIS B-1.4 vs 0.7 per 100,000
patients
HCV- patients have an increased risk of type 2 DM.
GALL BLADDER: acute cholecystitis postoperative complications are
higher
GALLSTONES MORE FREQUENT (2X)
lithogenic bile
hypomotility
prophylactic cholecystectomy.- not recommended
SOMATOSTATINOMA Triad- Gallstones, Diabetes,
Diarrhea/Steatorrhea
STEATOSIS in upto 80%
DM is a risk factor for HCC.
DIABETES -NAFLD
Spectrum of disease:
Simple steatosissteatohepatitis(NASH)  cirrhosis(20%).
Increase the risk of acute hepatic failure
Risk Factors: female, diabetes, obesity, hyperlipidemia
Fatty deposition, nuclear vacuolisation, cellular infiltration and
fibriosis
Cryptogenic cirrhosis  70% obese/50% diabetic!!
Cirrhosis of the liver may precede or cause diabetes→ glucose
intolerant & 30%-60% develop DM
TREATMENT
- Slow/gradual weight loss
- Control diabetes/hyperlipidemia
- Pharmacologic treatment: TZD’s, others
- Surgery:
Bariatric - improvement in 90%
Liver transplant(Cirrhotics)
PANCREAS
 DM for more than 5 years
 Pancreatitis can produce diabetes
 Exocrine pancreas secretion- Deteriorates
 Diabetes and pancreatitis:
Causes hyperglycemia
May persist for several months
Pancreatic calcifications
Degenerative complications-less frequent
 Exocrine secretion-reduced volume & enzymes
GALL BLADDER
 Higher incidence- unexplained
 Defect in the cholinergic pathway
 Reduced α-adrenergic tone
 Deficiency of cholecystokinin receptors
 Arteriolar disease impairing muscle contraction
 Hyperglycemia
 Hyperinsulinemia
CARCINOMAS
 Insulin resistance→secondary hyperinsulinemia →
↓IGF-binding proteins → ↑IGF-1 & Growth hormone
→ cancer growth(Pancreas, liver & colon).
 Loss of weight and deteriorated glycoregulation.
 New onset diabetes >50 yrs.
 HbA1c > 7.5% → young age, more advanced tumor
and poorer survival.
 Slow bowel transit time increase carcinogen exposure
Diabetes and GIT
Diabetes and GIT

Diabetes and GIT

  • 2.
    38 25 53 15 61 90 84 51 40 64 28 101 130 138 International Diabetes Federation.IDF Homepage. International Diabetes Federation 2011. Available from: http://www.idf.org/. Every 10 seconds... 2 people develop DM The number of patients with diabetes worldwide is expected to increase from 366 million in 2011 to 552 million in 2030 2 Number of patients, millions North America and Caribbean South and Central America Europe Africa India China Other s 2011 2030
  • 3.
     Disease duration Degree of glycemic control.
  • 6.
  • 9.
    EFFECTS  Peristalsis  Reflexiverelaxation  Sphincter tone  Vascular flow  Intestinal segmentation
  • 10.
    MOST COMMON PROBLEMS Constipation  Diarrhea  Abdominal pain  Nausea  Vomiting
  • 11.
    ESOPHAGUS • Abnormal Motility(50-75%) • Reduced number, amplitude & velocity of peristalsis • Increased spontaneous, spastic and repetitive contractions • Appearance of multipeaked contractions •Impaired(prolonged) esophageal transit- scintigraphy • Reduced lower esophageal sphincter pressure
  • 12.
     Hyperglycemia impairsneutrophil function and opsonization.  Odynophagia  ® Nystatin 1lakh U-3-5times/dy, Clotrimazole 10mg(troche) 5 times/dy or 500mg VT HS.  Fluconazole- 200mg loading + 100mg/dy x 21dys
  • 13.
    STOMACH Type 1: Gastritis/GastricAtrophy (5% to 10%). Parietal cell antibodies (15% to 25%). Pernicious Anemia (2.6% to 4%). Reduced acid hence decreased ulcer incidence. Increased risk of ulcer bleeding- microcirculatory changes that impair mucosal integrity.
  • 15.
    GASTROPARESIS DIABETICORUM  Seenin upto 60%  Insidious nature, Rarely acute- similar to vagotomy  Nausea, vomiting, pain, bloating, early satiety, flatulence, anorexia and postprandial regurgitation- 20%  Changes in drug absorption  Food retention- increase of bacteria toxins & fermentation products- hypermotility and diarrhoea Examination - succussion splash
  • 16.
    ● Scintigraphy- Solidand liquid emptying assessed. Gastroparesis->60% @ 2hrs & >10% @ 4hrs. ● Saline loading- 800-1000ml. ● EGG- Increased frequency of antral dysrhythmias. Phase 3 MMC are absent →bezoars.
  • 17.
  • 18.
    TREATMENT Glycemic control- Depo-insulinto prevent hypoglycaemic episodes  DIET MODIFICATION: Smaller/liquid meals, low-fat, low-fiber diet Jejunal tube feeding/ TPN  MEDICATIONS- Prokinetics: Metoclopramide10to20mg, Erythromycin 125mgBD or TDS or IV200mg over5to10minutesTDS, Domperidone 10 to 30 mg. Antiemetics- (promethazine or prochlorperazine), scopolamine patch. Low-dose TCA 5-HT3 receptor antagonists- odansetron, dronabinol Ghrelin- improves gastric emptying
  • 19.
    GES A) Gastric pacing- improves gastric emptying B) Neurostimulation - controls nausea/vomiting Endoscopic therapy with injection of botulinum toxin into the pyloric sphincter Gastric resection (Partial or complete) in medically refractory cases
  • 20.
    GASTRIC ELECTRICAL STIMULATION-10YEAR DATA - Greater Symptom Reduction - Improved Gastric Emptying  normalized in 23% - Decreased Hb A1C levels  translates to fewer complications - Significant Weight Gain - Reduction in Hospitalization Days - Reduced Medication Usage (for gastroparesis) McCallum, et al, Clin. Gastro & Hep. 9(4):314-319
  • 21.
    TABETIC PAIN  sharp,sudden pain  With nausea, vomiting, anorexia and weight loss- mimics intra-abdominal malignancy  Diabetic radiculopathy of thoracic nerve roots  The diagnosis- abnormal EMG of the anterior abdominal wall muscles
  • 22.
    DIABETIC ACIDOSIS  Anorexia,nausea and vomiting- 75%  Gastric dilatation- reduced gastric motility→vomiting-(ketones and systemic acidosis)  Abdominal pain-Acute apendicitis, Acute pancreatitis-should be excluded
  • 23.
    DIARRHEA  Drugs- Metformin,ά-Glucosidase inhibitors ,sugarfree sweeteners.  SIBO  Pancreatic insufficiency  Fast transit (and hyperthyroidism)  Celiac disease(4%)  Hormones- glucagon or somatostatin  Autonomic neuropathy
  • 24.
    CHRONIC DIARRHEA WITHOUT STEATORRHEA Occur 5-10 years later, men > women: 22%  Exact pathogenesis- still undetermined  In young-long standing and uncontrolled diabetes.  Diabetic night diarrhoea  Hyperglycaemia, hypoglycemia and ketoacidosis.  Barium transit- segmentation with mucous villous atrophy, irregularity.
  • 25.
    DIABETIC DIARRHEA WITH STEATORRHEA Steatorrhea occurs when diarrhoea worsens: 75%  Shows intermittent flow.  More frequently, postpardial and they appear at night  Rarely fatty, watery and abundant
  • 26.
    TREATMENT  Strict controlof blood glucose  Broad spectrum antibiotics  Vitamins, folic acid, liver extracts, bismuth, opiates, atropine  Corticosteroids  Clonidine (0.1 to 0.6 mg twice daily) stimulate intestinal absorption  Octreotide (50 to 100 subcutaneously, BD) in refractory diabetic diarrhea  Codeine sulfate (30 mg every six to eight hours),  Diphenoxylate with atropine (Lomotil),  Loperamide  Psyllium hydrophilic mucilloid
  • 27.
    DIABETES AND CELIAC DISEASE Coexist (4%)-shared HLA class II genes and non-HLA loci  Found within 4 years of DM.  Short stature, pubertal delay, - signs of vitamin deficit, anemia, losing weight and pigmentation,osteoporosis, and/or reproductive disorders  Have poor glycemic control- hypoglycemic episodes, and microvascular complications.  Small intestine which shows villous atrophy and abnormal superficial epithelium  Malabsorbtion in diabetes-limited only to fats  Respond to gluten free diet
  • 28.
    LARGE INTESTINE  Constipation Impaired gastrocolic reflex and delayed colonic transit  Ischemic colitis - luminal narrowing of submucosal arterioles.  Neuropathy damages the motility.  Equally frequent and severe without neuropathy  Obstipation- nausea, vomiting, belching and bloating.
  • 29.
    MEGASIGMOID SYNDROME  Colon dilatation-neuropathy and the paralysis of ganglia.  Imitates acute intestinal pseudo- obstruction.  Obstipation- long standing and refractory.  X-ray- dilatation of sigmoid colon.  Mucosa of the large intestine- Normal.  Bad prognosis.  Treatment- Laxative (abuse).
  • 30.
    FECAL INCONTINENCE  Thetotal stool volume is normal.  Steatorrhea in 30%.  Impaired internal anal sphincter resting tone and reflexive internal sphincter relaxation.  Reduced sensitivity of the rectum to distension.  Management: Antidiarrheal therapy Biofeedback training Sacral nerve stimulation Surgery In some patients incontinence remits spontaneously.
  • 31.
    DIABETES – LIVER/BILIARY HIGHERINCIDENCE OF ACUTE HEPATITIS B-1.4 vs 0.7 per 100,000 patients HCV- patients have an increased risk of type 2 DM. GALL BLADDER: acute cholecystitis postoperative complications are higher GALLSTONES MORE FREQUENT (2X) lithogenic bile hypomotility prophylactic cholecystectomy.- not recommended SOMATOSTATINOMA Triad- Gallstones, Diabetes, Diarrhea/Steatorrhea STEATOSIS in upto 80% DM is a risk factor for HCC.
  • 32.
    DIABETES -NAFLD Spectrum ofdisease: Simple steatosissteatohepatitis(NASH)  cirrhosis(20%). Increase the risk of acute hepatic failure Risk Factors: female, diabetes, obesity, hyperlipidemia Fatty deposition, nuclear vacuolisation, cellular infiltration and fibriosis Cryptogenic cirrhosis  70% obese/50% diabetic!! Cirrhosis of the liver may precede or cause diabetes→ glucose intolerant & 30%-60% develop DM
  • 33.
    TREATMENT - Slow/gradual weightloss - Control diabetes/hyperlipidemia - Pharmacologic treatment: TZD’s, others - Surgery: Bariatric - improvement in 90% Liver transplant(Cirrhotics)
  • 34.
    PANCREAS  DM formore than 5 years  Pancreatitis can produce diabetes  Exocrine pancreas secretion- Deteriorates  Diabetes and pancreatitis: Causes hyperglycemia May persist for several months Pancreatic calcifications Degenerative complications-less frequent  Exocrine secretion-reduced volume & enzymes
  • 35.
    GALL BLADDER  Higherincidence- unexplained  Defect in the cholinergic pathway  Reduced α-adrenergic tone  Deficiency of cholecystokinin receptors  Arteriolar disease impairing muscle contraction  Hyperglycemia  Hyperinsulinemia
  • 36.
    CARCINOMAS  Insulin resistance→secondaryhyperinsulinemia → ↓IGF-binding proteins → ↑IGF-1 & Growth hormone → cancer growth(Pancreas, liver & colon).  Loss of weight and deteriorated glycoregulation.  New onset diabetes >50 yrs.  HbA1c > 7.5% → young age, more advanced tumor and poorer survival.  Slow bowel transit time increase carcinogen exposure